|
Index | - | P/E | - | EPS (ttm) | -0.29 | Insider Own | 0.90% | Shs Outstand | 17.61M | Perf Week | -7.35% |
Market Cap | 10.60M | Forward P/E | - | EPS next Y | - | Insider Trans | 24.32% | Shs Float | 13.90M | Perf Month | -2.89% |
Income | -4.70M | PEG | - | EPS next Q | - | Inst Own | 9.50% | Short Float | 0.29% | Perf Quarter | -7.02% |
Sales | - | P/S | - | EPS this Y | -24.50% | Inst Trans | 0.18% | Short Ratio | 1.61 | Perf Half Y | -47.63% |
Book/sh | 0.61 | P/B | 0.98 | EPS next Y | - | ROA | - | Target Price | 4.00 | Perf Year | -68.80% |
Cash/sh | 0.50 | P/C | 1.21 | EPS next 5Y | - | ROE | - | 52W Range | 0.56 - 2.35 | Perf YTD | -56.52% |
Dividend | - | P/FCF | - | EPS past 5Y | 6.50% | ROI | - | 52W High | -74.31% | Beta | - |
Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 7.71% | ATR | 0.05 |
Employees | - | Current Ratio | - | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 41.83 | Volatility | 8.43% 8.10% |
Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 3.55 | Prev Close | 0.60 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 24.87K | Price | 0.60 |
Recom | 2.00 | SMA20 | -3.00% | SMA50 | -13.14% | SMA200 | -44.13% | Volume | 37,956 | Change | 0.25% |
![]() |
|
![]() | ||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York. | ||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite